Esperion Therapeutics, Inc. (ESPR)

2,0800 +0,0200 (+0,97%) Alla chiusura: 04:00PM EDT

Esperion Therapeutics, Inc.

3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States
734 887 3903
https://www.esperion.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 240

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Sheldon L. Koenig	President, CEO & Director	1,28M	N/D	1966
Dr. JoAnne Micale Foody FACC, M.D.	Chief Medical Officer	856,87k	N/D	1965
Mr. Eric J. Warren R.Ph.	Chief Commercial Officer	718,86k	N/D	1972
Mr. Benjamin Halladay M.B.A.	Chief Financial Officer	N/D	N/D	1986
Mr. Glenn P. Brame	Chief Technical Operations Officer	N/D	N/D	1958
Mr. Benjamin O. Looker J.D.	General Counsel & Corporate Secretary	550,35k	N/D	1982
Tiffany Aldrich M.B.A.	Associate Director of Corporate Communications	N/D	N/D	N/D
Ms. Betty Jean Swartz	Chief Business Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Governance aziendale

L'ISS Governance QualityScore di Esperion Therapeutics, Inc. al 1 maggio 2024 è 8. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 5; diritti degli azionisti: 8; retribuzione: 9.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.